Agency Leadership

EMA


EMA’s Conflict Of Interest Rules Must Not Limit Access To Experts And Risk Innovation, Warns Industry

 

The European Medicines Agency has published new policies on handling conflicts of interests for its scientific committee members, experts and management board members.

Andembry, Beyonttra, Rytelo Among 17 New Products To Receive EMA Backing

 

The European Medicines Agency has recommended several new products for pan-EU approval, including CSL Behring’s drug for hereditary angioedema and BridgeBio’s treatment for transthyretin amyloidosis in cardiomyopathy patients.

New EU Fee Regulation: Smaller Firms & Orphan Drugs Will Still Benefit From Full Reductions

 

While annual fees for marketing authorization applications and annual payments to the European Medicines Agency are set to increase from 2025, micro-sized companies and SMEs that make orphan drugs will still benefit from full reductions.

EMA Says No To Extending Clock-Stops For Immature Marketing Applications

 
• By 

The European Medicines Agency wants to discourage drug companies from submitting marketing applications with very interim data cuts and then expecting they can supplement their application with more data later on by requesting for extended clock-stops.

US FDA


Califf: US FDA Center Directors Should Engage With Staff Earlier To Avoid Public Disagreements

 

The outgoing FDA commissioner, who placed much of the blame for tough calls on small companies that conduct inadequate clinical programs, defended his policy to not overrule center directors, but added that he did not entirely exclude himself from some of the agency's most controversial drug reviews.

Exit Interview: US FDA’s Patrizia Cavazzoni Says CDER Staff In ‘Best Place Possible’

 
• By 

During a virtual appearance at a CERSI meeting two days after announcing retirement plans, the CDER director also said she wished agency reviews of unapproved drugs could be published.

RFK, Jr. Is Happening, Former Senator Burr Says

 

Industry should take a long-term view on policy issues, the former Republican legislator told biopharma execs at the J.P. Morgan Healthcare Conference.

Trump’s US FDA Reforms Need Center Director, Staff Support To Succeed, Former Leaders Say

 
• By 

Former FDA commissioners Mark McClellan and Scott Gottlieb, former acting commissioner Janet Woodcock and current commissioner Robert Califf offered advice on successfully implementing reforms and preventing a mass exodus of FDA employees as inklings emerge that the Trump team is already engaged on this front.